Evidence map›Paper›PMID 31557306›Full record

Trial reportClinical pharmacology and therapeutics2019

Pharmacogenomics and Placebo Response in a Randomized Clinical Trial in Asthma.

Rui-Sheng Wang, Damien C Croteau-Chonka, Edwin K Silverman, J Loscalzo, Scott T Weiss, Kathryn T Hall

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical pharmacology and therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Pharmacogenetics of Pediatric Asthma: Current Perspectives.Pharmacogenomics and personalized medicine · 2020
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Rui-Sheng WangChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Damien C Croteau-ChonkaChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Edwin K SilvermanChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
J LoscalzoDepartment of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Scott T WeissChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Kathryn T HallDivision of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Brigham and Women's Hospital · USHarvard University · US

Funding

Boston Biomedical Innovation CenterU54HL119145 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI GOLAN, DAVID E., LOSCALZO, JOSEPH · 2013 to 2021
$18.8M
TRANSLATIONAL PHARMACOLOGY COREP50GM107618 · NIGMS · HARVARD MEDICAL SCHOOL · PI SORGER, PETER KARL · 2014 to 2018
$10.8M
Center for Integrated Approaches to Undiagnosed DiseasesU01HG007690 · NHGRI · BRIGHAM AND WOMEN'S HOSPITAL · PI LOSCALZO, JOSEPH · 2014 to 2022
$10.4M
Epidemiological, pharmacogenomic and clinical impact of catechol-O-methyltransferase on cardiovascular diseaseK01HL130625 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI HALL, KATHRYN TAYO · 2016 to 2021
$921k
Weight loss-induced modification of the genomic network underlying obese asthmaK01HL127265 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI CROTEAU-CHONKA, DAMIEN C. · 2015 to 2019
$844k
NHGRI NIH HHS U01 HG007690NHLBI NIH HHS K01 HL127265NHLBI NIH HHS K01 HL130625NHLBI NIH HHS U54 HL119145NIGMS NIH HHS P50 GM107618
6 · The paper itself

Abstract

Genetic variation may differentially modify drug and placebo treatment effects in randomized clinical trials. In asthma, although lung function and asthma control improvements are commonplace with placebo, pharmacogenomics of placebo vs. drug response remains unexamined. In a genomewide association study of subjective and objective outcomes with placebo treatment in Childhood Asthma Management Program of nedocromil/budesonide vs. placebo (N = 604), effect estimates for lead single nucleotide polymorphisms (SNPs) were compared across arms. The coughing/wheezing lead SNP, rs2392165 (β = 0.94; P = 1.10E-07) mapped to BBS9, a gene implicated in lung development that contains a lung function expression quantitative trait locus. The effect was attenuated with budesonide (P

Indexed as

Placebo EffectAnti-Asthmatic AgentsAsthmaBudesonideChildCoughCytoskeletal ProteinsFemaleGenome-Wide Association StudyHumansMaleMicrotubule-Associated ProteinsNedocromilPatient Reported Outcome MeasuresPharmacogenomic TestingPolymorphism, Single NucleotideAnti-Asthmatic AgentsBBS9 protein, humanBudesonideCytoskeletal ProteinsKATNIP protein, humanMicrotubule-Associated ProteinsNedocromil

Identifiers

PMID31557306
PMCPMC6851426
OpenAlexW2975264981

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.